Bharat Rasayan Limited

Regd. Office: 1501, Vikram Tower, Rajendra Place, New Delhi - 110008
CIN: L24119DL1989PLC036264
Email: investors.brl@bharatgroup.co.in Website: www.bharatgroup.co.in

NOTICE is hereby given, pursuant to Regulation 29, 30 & 43 read with Regulations 33 & 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, May 28, 2025, inter-alia, to consider and approve the standalone & consolidated audited financial results of the Company for the quarter and year ended March 31, 2025.

The said Notice may be accessed on the Company's website at **https://www.bharatgroup.co.in** and may also be accessed on the Listed Stock Exchange website at **https://www.nseindia.com**.

Further, the Trading Window of the Company shall remain closed from May 8, 2025 to May 30, 2025 (both days inclusive) for the specified persons in terms of Code of Conduct of the Company to regulate, monitor and report of trading in Company's securities by insiders framed under the SEBI (Prohibition of Insider Trading) Regulations, 2015.

For BHARAT RASAYAN LIMITED
Sd/-
(NIKITA CHADHA)
Company Secretary

New Delhi
May 8, 2025

Cohance

Cohance Lifesciences Limited amalgamated with and into Suven Pharmaceuticals Limited
Effective Date – May 1, 2025
And
Name of Suven Pharmaceuticals Limited changed to Cohance Lifesciences Limited
Effective Date – May 7, 2025

This is to inform all concerned that pursuant to the order issued by Hon'ble National Company Law Tribunal dated March 27, 2025, Cohance Lifesciences Limited has been amalgamated with and into Suven Pharmaceuticals Limited, with effect from May 1, 2025 in terms of the Scheme of Amalgamation ("Scheme").

Further, pursuant to the said Scheme, the name of **"Suven Pharmaceuticals Limited" has been changed to "Cohance Lifesciences Limited"**, in terms of approval received from the Ministry of Corporate Affairs, Government of India, with effect from May 7, 2025.

For **Cohance Lifesciences Limited**
(Formerly Suven Pharmaceuticals Limited)
Sd/-
Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

Place : Hyderabad
Date : May 8, 2025

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad - 500081 Telangana, India. Tel: 91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai - 400093, Maharashtra, India. Tel: 91 22 61539999

LAKSHMI ELECTRICAL CONTROL SYSTEMS LIMITED

Regd.Office: 504, Avinashi Road, Peelamedu Post, Coimbatore - 641004
CIN : L31200TZ1981PLC001124
Website : www.lecsindia.com Email : contact@lecsindia.com

STATEMENT OF AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025

(₹ in Lakhs)

SL No	Particulars	3 Months Ended		12 Months Ended	
		31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)	31.03.2024 (Audited)
1.	Total income from operations	5,955.70	6,320.85	21,785.22	34,478.01
2.	Net Profit / (Loss) for the period (before Tax and Exceptional items)	371.86	285.73	618.79	1,905.68
3.	Net Profit / (Loss) for the period before Tax (after Exceptional items)	371.86	285.73	574.76	1,891.68
4.	Net Profit / (Loss) for the period after Tax (after Exceptional items)	270.36	208.25	347.23	1,396.01
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and other Comprehensive Income (after Tax)]	(985.31)	1,354.97	749.58	5,495.15
6.	Equity Share Capital (Face value of Rs.10/- each)	245.80	245.80	245.80	245.80
7.	Other Equity (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)	-	-	28,287.33	27,906.45
8.	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)				
	Basic :	10.99	8.47	14.12	56.79
	Diluted :	10.99	8.47	14.12	56.79

Note:

The above is an extract of the detailed format of Quarterly / Annual Audited Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly / Annual Audited Results are available on the Stock Exchange website- BSE Limited (www.bseindia.com) and on the Company website (www.lecsindia.com). (URL:https://www.lecsindia.com/investors/financial-results/). The results can be accessed by scanning the QR Code given below.

Coimbatore
8.05.2025

By order of the Board
NETHRA J. S. KUMAR
Chairperson and Managing Director

MULTI COMMODITY EXCHANGE CLEARING CORPORATION LIMITED

Exchange Square, Suren Road, Chakala, Andheri (East), Mumbai - 400 093, India
CIN: U74999MH2008PLC185349 | E-mail: ig-mcxccl@mcxccl.com | website: www.mcxccl.com

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025

(Rs. in lakh, except per share data)

PARTICULARS	Three months ended 31 March, 2025 Audited	Three months ended 31 December, 2024 Unaudited	Three months ended 31 March, 2024 Audited	Year ended 31 March, 2025 Audited	Year ended 31 March, 2024 Audited
1 Total Income from Operations	6,007	6,097	4,360	23,897	16,736
2 Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	3,281	3,759	2,428	14,336	3,282
3 Net Profit for the period before tax (after Exceptional and /or Extraordinary items)	3,281	3,759	2,428	14,336	3,282
4 Net Profit for the period after tax (after Exceptional and /or Extraordinary items)	3,292	3,739	2,405	14,327	3,259
5 Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	3,290	3,709	2,405	14,297	3,242
6 Equity Share Capital (of Rs. 10/- per share)	23,998.50	23,998.50	23,998.50	23,998.50	23,998.50
7 Reserves (excluding Revaluation Reserves as shown in the Audited Balance Sheet of previous year)	-	-	-	(3,986)	(16,868)
8 Earnings Per equity share (of Rs. 10/- each)* Basic and Diluted (Rs.):	1.37	1.56	1.00	5.97	1.36

** Earnings per share for the interim period is not annualised.*

Notes:

1. The above is extract of the detailed format of Quarterly Financial Results. The full format of the Quarterly Financial Results are available on the Company's website at **www.mcxccl.com**
2. The above results have been reviewed by the Audit Committee held on May 07, 2025 and approved by the Board of Directors at their meeting held on May 08, 2025.

Place: Mumbai
Date: May 08, 2025

Scan QR code for the complete financial result

OR Visit: https://www.mcxccl.com/disclosures/financial-results

For **Multi Commodity Exchange Clearing Corporation Limited**
sd/-
Narendra Kumar Ahlawat
Managing Director & CEO

NIVA BUPA HEALTH INSURANCE COMPANY LIMITED

REGISTRATION NO: 145, DATE OF REGISTRATION WITH IRDAI: FEBRUARY 15, 2010

niva Bupa Health Insurance

Financial Results

Rs. in Lakhs

SN	Particulars	Three months ended / As at		Year ended / As at	
		March 31, 2025	March 31, 2024	March 31, 2025	March 31, 2024
		Audited	Audited	Audited	Audited
1	Premium Income (Gross) **(Note 1)**	2,07,865	1,75,944	6,76,223	5,60,757
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	20,608	15,706	21,352	8,185
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	20,608	15,706	21,352	8,185
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	20,608	15,706	21,352	8,185
5	Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)] **(Note 2)**	NA	NA	NA	NA
6	Paid up Equity Share Capital	1,82,703	1,69,954	1,82,703	1,69,954
7	Reserves (Excluding Revaluation Reserve)	1,23,129	35,005	1,23,129	35,005
8	Earnings Per Share (face value of Rs. 10/- each)				
	(i) Basic (in Rs.)	1.13	0.92	1.22	0.51
	(ii) Diluted (in Rs.)	1.11	0.90	1.20	0.50
9	Securities Premium Account	1,94,961	1,28,169	1,94,961	1,28,169
10	Net Worth	3,05,832	2,04,959	3,05,832	2,04,959
11	Outstanding Debt	25,000	25,000	25,000	25,000
12	Debt Equity Ratio (No. of times) **(Note 3)**	0.08	0.12	0.08	0.12
13	Debt Service Coverage Ratio (No. of times) **(Note 4)**	32.24	24.61	8.98	4.06
14	Interest Service Coverage Ratio (No. of times) **(Note 5)**	32.24	24.61	8.98	4.06
15	Debenture Redemption Reserve **(Note 6)**	NA	NA	NA	NA

Notes:

1. Premium Income is gross of reinsurance and net of Goods and Services tax.
2. The Indian Accounting Standards (Ind AS) are currently not applicable to Insurance Companies in India.
3. Debt Equity Ratio is calculated as Total Borrowings divided by Net Worth.
4. Debt-Service Coverage Ratio is computed as Profit before Interest and Tax divided by Interest expense together with principal repayments of long term debt made during the year.
5. Interest-Service Coverage Ratio is computed as Profit before Interest and Tax divided by Interest expense of long term debt.
6. The provisions of Section 71 of the Companies Act, 2013 read with Rule 18 of the Companies (Share Capital and Debentures) Amendment Rules, 2014 are applicable to the Company. However, as per Rule 18, Debenture Redemption Reserve shall be created out of profits of the Company available for payment of dividend, since the Company's equity shares are listed as at March 31, 2025 and the Company does not have profits which are available for payment of dividend, hence no Debenture Redemption Reserve is being created.
7. The above is an extract of the detailed format of Quarterly and Year to date Financial Results filed with the Stock Exchange under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of Quarterly and Year to date Financial Results are available on the website of Stock Exchanges (www.nseindia.com) & (www.bseindia.com) and the Company's website (www.nivabupa.com). The said Financial Results have been reviewed by the Audit Committee and are approved by the Board of Directors in the meeting held on May 07, 2025 and such results were reviewed by the Joint Statutory Auditors.

Place: New Delhi
Date: May 07, 2025

The Financial Results can be accessed by scanning this QR Code.

For and on behalf of Board of Directors
Sd/-
Krishnan Ramachandran
Managing Director & Chief Executive Officer
(DIN:08719264)

Insurance is a subject matter of solicitation. Niva Bupa Health Insurance Company Limited (IRDAI Registration Number 145). 'Bupa' and 'HEARTBEAT' logo are registered trademarks of their respective owners and are being used by Niva Bupa Health Insurance Company Limited under license. IRDAI Registration No. 145. Registered Office: C-98, First Floor, Lajpat Nagar, Part 1, New Delhi-110024, Corporate Office: 3rd Floor, Capital Cyberscape, Golf Course Extension Road, Sector-59, Gurugram -122011 (Haryana). CIN No. L66000DL2008PLC182918. Customer Helpline No.: 1860-500-8888. Website: www.nivabupa.com.